Product Description
Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Chiron
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Korea, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Bipolar Disorder|COVID-19|Conjunctivitis, Allergic|Kidney Cancer|Renal Cell Carcinoma|Rhinitis, Allergic, Seasonal
Phase 1: Breast Cancer|Cervical Cancer|Gastrointestinal Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Pro2022002198 | P1 |
Recruiting |
Lung Cancer|Gastrointestinal Cancer|Cervical Cancer|Breast Cancer|Uterine Cancer |
2026-09-01 |
|
| ATB-301-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-08-21 |
27% |
| ATB-301-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-08-21 |
27% |
| Rhinil-2 | P2 |
Completed |
Conjunctivitis, Allergic|Rhinitis, Allergic, Seasonal |
2022-08-16 |
|
| DEPIL-2 | P2 |
Completed |
Bipolar Disorder |
2022-05-20 |